Cytosorbents Corporation CTSO
$5.75
$0.020.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -84.61% | 26.45% | 60.43% | 47.95% | 62.27% |
| Total Depreciation and Amortization | -9.48% | -6.09% | -6.48% | -20.74% | -20.68% |
| Total Amortization of Deferred Charges | 32.81% | 64.38% | 115.22% | 301.05% | -- |
| Total Other Non-Cash Items | 268.57% | -135.28% | -165.54% | -155.62% | -149.44% |
| Change in Net Operating Assets | 2.15% | 120.02% | 76.48% | 60.00% | 123.77% |
| Cash from Operations | 6.46% | 22.90% | 14.22% | 46.51% | 53.95% |
| Capital Expenditure | 42.31% | 28.16% | 42.25% | 59.74% | 13.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 16.37% | 1.49% | 15.06% | 66.79% | -0.97% |
| Cash from Investing | 54.32% | 29.71% | 37.97% | 63.58% | 5.88% |
| Total Debt Issued | -- | -83.48% | -83.48% | -100.00% | -100.00% |
| Total Debt Repaid | -- | -- | -- | 100.00% | 100.00% |
| Issuance of Common Stock | -100.00% | -100.00% | 3,002.18% | -42.94% | -45.80% |
| Repurchase of Common Stock | -- | -- | -- | -- | -20,400.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | 92.66% |
| Cash from Financing | -64.08% | -85.19% | -0.24% | -67.26% | -68.81% |
| Foreign Exchange rate Adjustments | 336.74% | 2,064.97% | 1,852.94% | 142.53% | 289.25% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -79.96% | -324.50% | 65.94% | -246.59% | -3,161.85% |